Dataset Information

Impact of Helicobacter pylori eradication timing on the risk of thromboembolism events in patients with peptic ulcer disease: a population-based cohort study.

ABSTRACT:

Objectives

To evaluate the impact of Helicobacter pylori eradication on venous thromboembolism (VTE) events, and the differences between early and late treatment timing.

Design

A population-based cohort study.

Setting

Taiwan's National Health Insurance Research Database.

Participants

A total of 6736 patients who received H. pylori eradication therapy from 2000 to 2010 were identified. We randomly selected 26 944 subjects matching in gender, age and baseline year as comparison cohort.

Primary and secondary outcome measures

The incidence rate ratios of VTE in the H. pylori eradication cohorts to that of the control cohort were examined. Multivariable Cox proportional hazard regression analysis was used to estimate the relative HRs and 95% CI of VTE development.

Results

The total incidence rate of VTE was observed in the late H. pylori eradication cohort, the early H. pylori eradication cohort and the control cohort (15.2, 3.04 and 2.91 per 1000 person-years, respectively). An age-specific trend was found in the late H. pylori eradication cohort, with a greater rate of VTE in the 50-65 years and more than 65 years age groups (adjusted HR 5.44; 95% CI 4.21 to 7.03 and 3.13; 95% CI 2.46 to 3.99). With comorbidities, the late H. pylori eradication cohort seemed to have the highest VTE incidence rate and adjusted HR (4.48, 95% CI 3.78 to 5.30).

Conclusions

Late H. pylori eradication was associated with a significantly increased risk of VTE, and there was a significantly greater risk of VTE in patients with female gender, age more than 50 years and with comorbidities.

SUBMITTER: Lai JN

PROVIDER: S-EPMC9413183 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Impact of <i>Helicobacter pylori</i> eradication timing on the risk of thromboembolism events in patients with peptic ulcer disease: a population-based cohort study.

Lai Jung-Nien JN Liao Yi-Jun YJ Lin Cheng-Li CL Chang Chi-Sen CS Peng Yen-Chun YC

BMJ open 20220824 8

<h4>Objectives</h4>To evaluate the impact of <i>Helicobacter pylori</i> eradication on venous thromboembolism (VTE) events, and the differences between early and late treatment timing.<h4>Design</h4>A population-based cohort study.<h4>Setting</h4>Taiwan's National Health Insurance Research Database.<h4>Participants</h4>A total of 6736 patients who received <i>H. pylori</i> eradication therapy from 2000 to 2010 were identified. We randomly selected 26 944 subjects matching in gender, age and base ...[more]

PMID: 36002209

Similar Datasets

Project description:BackgroundMost peptic ulcer cases are associated with Helicobacter pylori (H. pylori) infection or the use of nonsteroidal anti-inflammatory drugs (NSAIDs). H. pylori eradication therapy is recommended for the treatment of H. pylori-positive peptic ulcers. We aimed to assess and validate the cumulative economic and health effects of H. pylori eradication strategy for the treatment of peptic ulcers compared with PPI therapy strategy.Materials and methodsWe developed a cohort state-transition model for H. pylori eradication strategy and PPI therapy strategy over a lifetime horizon from a healthcare payer perspective. We targeted two hypothetical cohorts of H. pylori-positive patients with gastric and duodenal ulcers aged 20, 30, 40, 50, 60, 70, and 80. The main outcomes were costs, quality-adjusted life-years (QALYs), life expectancy life-years (LYs), incremental cost-effectiveness ratios, ulcer recurrence cases, and ulcer-associated deaths. One-way and probabilistic sensitivity analyses were conducted to assess the impact of uncertainty.ResultsIn the base-case analysis, H. pylori eradication strategy was less costly with greater benefits than PPI therapy strategy in all age groups. Cost-effectiveness was not sensitive to any variables in all age groups. Sensitivity analyses showed strong robustness of the results. From 2000 to 2020, H. pylori eradication strategy saved US$14.07 billion over a lifetime, increased 8.65 million QALYs and 1.23 million LYs over a lifetime, and prevented 551,298 ulcer recurrence cases and 59,465 ulcer-associated deaths, compared with PPI therapy strategy.ConclusionsH. pylori eradication strategy not only has contributed significantly to preventing ulcer recurrence and reducing ulcer-associated deaths but also has resulted in great cost savings. All over the world, H. pylori eradication strategy is likely to have yielded a comparable magnitude of economic and health benefits, depending on the epidemiology of H. pylori-related peptic ulcers and the healthcare environment in each country.

Project description:BackgroundThe incidence of peptic ulcer disease (PUD) has been increasing yearly, especially in the adolescent population. The eradication of Helicobacter pylori (H. pylori) may reduce recurrence and bleeding to some extent, but it does not completely change the clinical status of PUD. Therefore, this study aims to analyze the risk factors for ulcer recurrence and upper gastrointestinal bleeding after H. pylori eradication therapy in order to provide a reference for reducing the risk of PUD and improving the quality of life of patients.MethodsWe retrospectively analyzed 536 adolescent patients who developed peptic ulcer and received H. pylori eradication therapy from June 2016 to July 2021. The relationship between the clinical characteristics of the patients and gastrointestinal bleeding and recurrence was analyzed using the t-test and chi-squared test. Binary logistic regression was used to analyze the independent risk factors for the occurrence of bleeding and recurrence.ResultsA total of 536 patients were included in this retrospective study. Gender, history of ulcers, number, size, location and staging of ulcers, and application of nonsteroidal anti-inflammatory drugs (NSAIDs), and other characteristics were significantly different between the bleeding and nonbleeding groups (P<0.05); family history of upper gastrointestinal ulcer, history of ulcers, number and size of ulcers and application of NSAIDs, and other characteristics were significantly different between the recurrent and nonrecurrent groups (P<0.05). Binary logistic regression analysis showed that history of ulcers, number and location of ulcers, coagulation abnormalities, and other characteristics were independent risk factors for the occurrence of bleeding; the occurrence of previous bleeding, number and size of ulcers, and other characteristics were independent risk factors for recurrence.ConclusionsIn the clinical treatment of adolescent patients, it is important to pay high attention to clinical characteristics, such as the patient's previous ulcer history, the size, number and location of ulcers, and coagulation function, so as to adopt individualized treatment methods to effectively reduce the harmfulness of the disease in response to the risk factors of ulcer bleeding and recurrence after H. pylori eradication therapy. This can decrease the occurrence of complications and improve the prognosis of patients.

Project description:BackgroundClarithromycin-based therapy is important for Helicobacter pylori eradication treatment. However, clarithromycin may increase cardiovascular risk. Hence, we investigated the association between clarithromycin use and outcomes in adults with stable coronary heart disease (CHD) and subsequent peptic ulcer disease (PUD).MethodsThis nationwide cohort study used a national health insurance database to screen 298,417 Taiwanese residents who were diagnosed with coronary heart disease from 2001 to 2015 for eligibility in the study and to evaluate select eligible patients with CHD-PUD from 2004 to 2015. Data were obtained from new users of clarithromycin (n = 4183) and nonusers of clarithromycin (n = 24,752) during follow-up. A total of 4070 eligible clarithromycin users and 4070 nonusers were subject to final analysis by 1:1 propensity score matching. Participants were followed up after receiving clarithromycin or at the corresponding date until the occurrence of cardiovascular morbidity in the presence of competing mortality, overall mortality and cardiovascular mortality, or through the end of 2015. The incidence rates and risks of overall mortality and cardiovascular outcomes were evaluated. The associations between clarithromycin and arrhythmia risk, as well as its dose and duration and overall mortality and cardiovascular outcomes were also addressed.ResultsClarithromycin users were associated with adjusted hazard ratios of 1.08 (95% confidence interval, 0.93-1.24; 21.5 compared with 21.2 per 1000 patient-years) for overall mortality, 0.95 (0.57-1.59; 1.5 compared with 1.8 per 1000 patient-years) for cardiovascular mortality, and 0.94 (0.89-1.09; 19.6 compared with 20.2 per 1000 patient-years) for cardiovascular morbidity in the presence of competing mortality, as compared with nonusers. We found no relationship between dose and duration of clarithromycin and overall mortality and cardiovascular outcomes and no increased risk of arrhythmia during follow-up period. After inclusion of arrhythmia events to re-estimate the risks of all study outcomes, the results remained insignificant.ConclusionConcerning overall mortality, cardiovascular mortality, and cardiovascular morbidity, our results suggest clarithromycin-based therapy for Helicobacter pylori eradication may be safe in patients with stable CHD and subsequent PUD.